Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | ETV6 | P41212 | 3/20 | 0.39 |
| ▸ | RET | P07949 | 4/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120068 | 0.91 | ALOX5 (0.53) | ALOX5EPHX2MAPTTP53GAA | |
| SCHEMBL15179409 | 0.88 | CNR2 (0.42) | ALOX5MAPTTP53GAASMN1; SMN2 | |
| SCHEMBL15179450 | 0.87 | GAA (0.44) | ALOX5MAPTTP53GAACNR2 | |
| SCHEMBL10120106 | 0.85 | CNR2 (0.43) | MAPTTP53GAACNR2KDR | |
| SCHEMBL10120303 | 0.85 | GAA (0.45) | ALOX5MAPTTP53GAACNR2 | |
| SCHEMBL10120112 | 0.84 | CNR2 (0.41) | CNR2KDRETV6RET | |
| SCHEMBL15179454 | 0.83 | ALOX5 (0.54) | ALOX5EPHX2MAPTTP53GAA | |
| SCHEMBL15179316 | 0.82 | ALOX5 (0.45) | ALOX5EPHX2MAPTTP53GAA | |
| SCHEMBL15179467 | 0.81 | KDM4E (0.40) | GAACNR2KDRETV6RET | |
| SCHEMBL15179464 | 0.80 | CNR2 (0.39) | GAACNR2KDRETV6RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601194-B1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME (US) | 2016-05-25 | — | — | EP | disclosed |
| US-8871929-B2 | Fused-imidazoyl compounds useful as antimicrobial agents | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871929-B2 | Fused-imidazoyl compounds useful as antimicrobial agents | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012018662-A2 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | SCHERING CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPS4Y1 | ALOX5 4416/4885EPHX2 3506/4885MAPT 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.